Prevalence of Low FIB-4 in MASLD-Related Hepatocellular Carcinoma: A Multicentre Study
- PMID: 39462858
- DOI: 10.1111/apt.18346
Prevalence of Low FIB-4 in MASLD-Related Hepatocellular Carcinoma: A Multicentre Study
Abstract
Background: Major society guidelines recommend the fibrosis-4 index (FIB-4) as the initial step to risk stratifying people with metabolic dysfunction-associated steatotic liver disease (MASLD). We aimed to evaluate the proportion of people with MASLD-related hepatocellular carcinoma (HCC) and a low FIB-4.
Methods: This cohort study included 613 consecutive adults (33% female) diagnosed with MASLD-related HCC from January 2008 to August 2023 at seven international centres in Australia, India, Japan, South Korea, Singapore and the United States. The primary objective was to determine the proportion of participants with a low FIB-4, defined as FIB-4 < 1.3, or < 2 if age > 65 years, in people without cirrhosis.
Results: The mean (±SD) age and body mass index were 71 (±11) years and 27 (±7) kg/m2, respectively. Overall, 235 participants (38%) did not have known cirrhosis. The median FIB-4 was 3.90 (IQR 2.42-6.42). A total of 78 participants (13%) had a low FIB-4. Among participants without known cirrhosis (n = 235), 62 participants (26%) had a low FIB-4. Participants with a low FIB-4 had larger median total tumour diameter (p < 0.001) and lower median serum alpha-fetoprotein (p = 0.005), compared to participants without a low FIB-4. Cirrhosis was associated with lower odds of low FIB-4, but not other factors such as male sex, type 2 diabetes, or obesity.
Conclusion: More than a quarter of those with MASLD-related HCC without cirrhosis have a low FIB-4. The proposed clinical care pathways may not identify these people for further evaluation.
Keywords: MASH; hepatoma; liver cancer; surveillance.
© 2024 John Wiley & Sons Ltd.
References
-
- Z. M. Younossi, A. B. Koenig, D. Abdelatif, Y. Fazel, L. Henry, and M. Wymer, “Global Epidemiology of Nonalcoholic Fatty Liver Disease‐Meta‐Analytic Assessment of Prevalence, Incidence, and Outcomes,” Hepatology 64, no. 1 (2016): 73–84.
-
- C. Estes, Q. M. Anstee, M. T. Arias‐Loste, et al., “Modeling NAFLD Disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and the United States for the Period 2016–2030,” Journal of Hepatology 69, no. 4 (2018): 896–904.
-
- K. Riazi, H. Azhari, J. H. Charette, et al., “The Prevalence and Incidence of NAFLD Worldwide: A Systematic Review and Meta‐Analysis,” Lancet Gastroenterology & Hepatology 7, no. 9 (2022): 851–861.
-
- D. Q. Huang, H. B. El‐Serag, and R. Loomba, “Global Epidemiology of NAFLD‐Related HCC: Trends, Predictions, Risk Factors and Prevention,” Nature Reviews Gastroenterology & Hepatology 18, no. 4 (2021): 223–238.
-
- R. Loomba and A. J. Sanyal, “The Global NAFLD Epidemic,” Nature Reviews. Gastroenterology & Hepatology 10, no. 11 (2013): 686–690.
Publication types
MeSH terms
Grants and funding
- U01DK061734/DK/NIDDK NIH HHS/United States
- 5UL1TR001442/TR/NCATS NIH HHS/United States
- NCSP2.0/2023/NUHS/DH/NUHS Clinician Scientist Programme
- R01DK121378/DK/NIDDK NIH HHS/United States
- RP124/John C Martin Foundation
- R01DK106419/DK/NIDDK NIH HHS/United States
- P30DK120515/DK/NIDDK NIH HHS/United States
- P01HL147835/HB/NHLBI NIH HHS/United States
- R01 DK121378/DK/NIDDK NIH HHS/United States
- R01 DK106419/DK/NIDDK NIH HHS/United States
- U01DK130190/DK/NIDDK NIH HHS/United States
- UL1 TR001442/TR/NCATS NIH HHS/United States
- R01DK124318/DK/NIDDK NIH HHS/United States
- MOH-001370/Singapore Ministry of Health's National Medical Research Council
- MOH-001566/Singapore Ministry of Health's National Medical Research Council
- P30 DK120515/DK/NIDDK NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical